SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Strategies & Market Trends : Stock Watcher's Thread / Pix of the Week (POW) -- Ignore unavailable to you. Want to Upgrade?


To: Stock Watcher who wrote (43660)3/6/2001 11:19:08 AM
From: Joe Copia  Read Replies (1) | Respond to of 52051
 
NTXY news and good index candidate?

Message 15455018



To: Stock Watcher who wrote (43660)3/6/2001 4:51:24 PM
From: Stock Watcher  Read Replies (1) | Respond to of 52051
 
*Tues. Index Gainer's (+20% or more), NXWX + 32%, all results here:

NXWX + 32% (Fav's)

IFCC + 24.5% (Bernard Ng)

MIGR + 23% (RCJIII)

TMWD + 23% (Fav's)

Index #1 ($2 - $6.99):
siliconinvestor.com

Index #2 ($7 & over):
siliconinvestor.com

Index #3 (under $2):
siliconinvestor.com

Favorite's Index:
siliconinvestor.com



To: Stock Watcher who wrote (43660)3/7/2001 8:12:11 AM
From: Joe Copia  Read Replies (1) | Respond to of 52051
 
only 4.6 OS New ticker today VCMI. Rub elbows with a "JAG" officer:

Message 15460293



To: Stock Watcher who wrote (43660)3/9/2001 10:18:16 AM
From: Joe Copia  Read Replies (1) | Respond to of 52051
 
This could be fun when Europeons see this:

SSP who wrote (81523)
From: lindao
Thursday, Mar 8, 2001 7:37 PM
View Replies (2) | Respond to of 81555

Vitro Files Patent: May Prevent 'Mad Cow Disease' Spread to Biotech Products
Jump to first matched term

A STORY WITH SIZZLE!

LITTLETON, Colo., March 8 /PRNewswire/ -- Vitro Diagnostics, Inc. (OTC Bulletin
Board: VODG) announced today that it has filed a patent application with the United States
Patent and Trademark Office entitled "Defined Medium for the Culture of Human Cells."

This filing seeks patent protection for the Company's specially formulated, liquid cell culture
medium, which can be used to grow human cells in a manner that ensures their protection
against infection by "Mad Cow Disease." Biotechnology scientists often grow their
product-producing cells in a medium containing fetal bovine serum. With the
ever-increasing spread of "Mad Cow Disease," there is a high demand for media
that can guarantee that "Mad Cow Disease" would not be spread via therapeutic
interventions.

The Company has derived a specialty medium that is optimal for the proliferation of human
cells in cell culture. This medium is serum-free and contains clearly defined components
that are available from non-animal sources. This medium is necessary for production of
biopharmaceutical materials that originate from cultured human cells. Current FDA
guidelines suggest the use of defined, serum-free culture medium to produce biological
therapeutic products because of concerns regarding the introduction of contamination into
drug products.

The Company's product pipeline includes various forms of purified FSH and related
products for use in the treatment of infertility. A plan for the approval of its first product,
VITROPIN(TM), is under review by the FDA. VITROPIN(TM) is a highly purified form
of urinary FSH produced through the Company's patented method. Additional
patent-pending products include VITROPIN-C(TM), custom FSH that reduces side effects
of current products, VITROPIN-V(TM), a breakthrough FSH product produced from a
proprietary immortalized cell line, and VITROJECT(TM), a novel drug injection device for
administration of FSH and other drugs.

VITROCELL-X(TM) is the designation of a series of immortalized cell lines in which "X"
represents the organ from which the cell line was derived, and each of which produces
"natural therapeutic" products. For example, "VITROCELL-PG(TM)" is a cell line derived
from the human pituitary gland that produces FSH. VITROCELL-X(TM) cell lines are
produced by the Company's proprietary platform technology method, VITROCELL-X(TM)
CELL IMMORTALIZATION TECHNOLOGY, which uses the controlled
over-expression of specific genes to produce cellular immortalization.

The newly discovered medium that is the subject of the recently filed patent application
would be used in the production of "Naturally Pure Therapeutics"(TM) from immortalized
human cells.

Additional information may be accessed through the Company's web site at
www.vitrodiag.com



To: Stock Watcher who wrote (43660)3/20/2001 7:37:42 AM
From: Joe Copia  Read Replies (2) | Respond to of 52051
 
One to watch. Down on very small volume from .99 last week. VCMI.

The Penny Analyst Report

The Penny Analyst is proud to highlight a company that has a rare quality among micro cap stocks… profits. Valencia Entertainment (OTCBB: VCMI), launched in 1995 by Vince Vellardita, has reached profitability in just a few short years. As CEO, Vince has drawn on his vast experience in the entertainment industry, which began as a top music producer, to achieve success at Valencia in such a short period of time. Vince has over twenty years experience in the industry, including time spent creating satellite networks and developing facilities throughout the country.
Valencia Entertainment is based in the heart of Southern California’s entertainment industry and operates a number of successful divisions, which include Studios, Television, Motion Picture, and New Media.

Studio Division

The studio facility, located in Valencia California is housed on 12 acres of land, has 6 stages totaling 120,000 square feet and is valued at ten million dollars. The complex has 50,000 square feet of furnished production offices, complete video /audio control room, in-house lighting and grip packages, and 24 hour access and security. With amenities such as these its no wonder Valencia’s clients include: Warner Bros., Paramount, Universal, MGM, HBO, NBC, 20th Century Fox, Disney, Saban, ABC, CBS, Sony, Showtime, and USA Network. Valencia also plans to build on their already phenomenal success by adding another facility, located in New York. With such a long list of clients its no surprise that Valencia’s studio facilities have a 95% occupancy rate.

Television Division

In addition to the profitable facilities management business, Valencia is also involved in television production. By partnering with other entities into co-productions Valencia is able to add content to its entertainment library while minimizing risk. Current projects include: Truster (pilot episode), PCH (22 one-hour episodes), Fuhgedabowdit, AJ’s Time Travelers (40 half-hour episodes), Frankie Avalon’s Let’s Do It Again, and NASA: Amazing Experiments in Space.
PCH is based on the movie of the same name. PCH seems to have all the elements of a runaway hit: Beautiful women, sandy Southern California beaches, and characters that are young, rich and famous. Fuhgedaboedit is a comedy series about a Mafia boss who decides to retire and leave his crime empire to an unlikely heir, his daughter. The Truster pilot is based on a new advancement in software that allows users to analyze a speaker’s voice to determine the truthfulness of his or her statements. Other Television programs are in the development stages.

Motion Picture Division

Valencia’s Motion Picture Division, similar to its Television unit, also ventures into co-productions. The main focus of the Motion Picture Division is to operate in a low-risk, cost-efficient manner while producing mainstream motion pictures and made-for-television movies with a worldwide appeal. Current projects include: PCH (the movie), The Life, Jumped In, Officer Down, and One White Lie with many more still in development.

New Media Division

The goal of the New Media Division is to focus on technological breakthroughs while also capitalizing on the potential entertainment value as well. This is evident in the creation of the Truster television pilot, which is based on the Truster truth detection software now available from the Web site www.trusterusa.com. Another project developed by the New Media Division is “Hangin’ With the Boyz.” This is a Web site where fans may learn about their favorite athletes. Fans can read player biographies, download pictures, and even view stats, The web site, located at www.hanginwiththeboyz.com contains profiles of top athletes from different sports.

Profitability with Minimal Risk

Valencia seems to have figured out a very unique way to turn a profit in the highly competitive entertainment industry. The core of their business is in the facilities rentals, which are near capacity and provide a steady revenue stream. However, by becoming involved with partners in the production of various movies and television programs they are in a position to reap huge profits with minimal risk if just one program becomes successful. In addition, by becoming involved in technological advances and its entertainment value, Valencia appears to be taking the lead in aggressively seeking out new revenue sources. With a business model such as this, it should come as no surprise that Valencia Entertainment has grown at such a quick pace and has reached profitability in such a short time.



To: Stock Watcher who wrote (43660)3/26/2001 10:27:21 AM
From: Joe Copia  Read Replies (1) | Respond to of 52051
 
ECHTA.....SNUS had similar news about FDA and stock went from .50 to 2.50 in one
day....float 8 mil

ECHTA float is 500k!!! look at what the Director (insider) paid for 1.3 mil shares. $0.75!!

biz.yahoo.com

EchoCath's Portable Blood Velocity Measurement System Receives FDA 510K Clearance-To-Market

PRINCETON, N.J.--(BUSINESS WIRE)--March 26, 2001--EchoCath, Inc. (NASD-OTC:ECHTA) announced today it has been granted permission by the U.S. Food and Drug Administration to market its EchoFlow(TM) battery powered, portable blood velocity measurement system (EchoFlow PEF-1).

EchoFlow PEF-1 is a battery powered and portable angle-independent blood velocity measuring system that enables physicians to evaluate and quantify blood flow in vessels using ultrasound technology. Blood velocity is an important parameter of circulatory system health. In addition to EchoCath's EchoFlow(TM) BVM-1 system designed for use in the operating room for blood velocity measurement, the EchoFlow(TM) PEF-1 extends the usefulness of EchoCath's proprietary ultrasound technology. Intensive care units, dialysis facilities and clinics are areas of hospitals where physicians have had the need for accurate blood velocity measurement but have not had cost
effective readily available equipment. The EchoFlow(TM) PEF-1 system addresses these needs.

EchoCath President, Frank DeBernardis commented, ``We are pleased that surgeons who have been using our EchoFlow(TM) BVM-1 in clinical evaluations have been impressed with the systems and have identified a number of applications for the technology outside of the operating room. The EchoFlow(TM) PEF-1 is EchoCath's response to their input.'' The Company will be exhibiting this technology at the Society for Clinical Vascular Surgery 29th Annual Symposium in Boca Raton, Florida on April 5-7th.

Certain statements herein constitute ``forward-looking statements'' within the meaning of the Private
Securities Litigation Reform Act of 1995, including without limitation statements regarding
acceptability by vascular surgeons and physicians of the Company's technology. Such
forward-looking statements involve known and unknown risks, uncertainties and other factors which
may cause the actual results, performance or achievements of the Company to be materially different
from any future results, performance or achievements expressed or implied by such forward-looking
statements. Such factors include, among others, the following: limited commercial operations; no
assurances of success; need for additional financing; uncertainty of market acceptance; failure to
receive or delays in receiving regulatory approval; lack of a distribution channel for the Company's
products; and limitations on third party reimbursement. Readers are cautioned not to place undue
reliance on these forward-looking statements, which speak only as of the date hereof.

Contact:

EchoCath, Inc.
Frank DeBernardis, 609/987-8400



To: Stock Watcher who wrote (43660)3/28/2001 10:11:16 AM
From: Joe Copia  Read Replies (1) | Respond to of 52051
 
MMCI Book Value .88

biz.yahoo.com

must read:

Message 15575070